BRTX BioRestorative Therapies, Inc.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1505497 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.5%
TTM net income YoY8.6%
TTM EPS YoY27.9%
Revenue 3-yr CAGR38.4%
Net income 3-yr CAGR—
Margins
Gross margin92.1%
Operating margin-3,975.0%
Net margin-3,089.6%
FCF margin—
EBITDA margin-3,916.2%
Returns
ROE-241.1%
ROA-147.7%
ROIC (approx.)-465.4%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets34.8%
Debt / equity0.00x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $359,700 | $401,000 |
| Cost of revenue | $23,844 | $28,072 |
| Gross profit | $335,856 | $372,928 |
| R&D expense | $10.09M | $6.71M |
| SG&A expense | $5.89M | $5.22M |
| Operating income | -$15.65M | -$11.56M |
| Pretax income | -$14.20M | -$8.98M |
| Net income | -$14.24M | -$8.98M |
| EBITDA | -$15.44M | -$11.37M |
| EPS (basic) | -1.58 | -1.16 |
| EPS (diluted) | -1.58 | -1.16 |
| Weighted avg. shares (diluted) | 8.99M | 7.76M |
| Banking | ||
| Net interest income | $266,207 | $616,077 |
| Balance sheet | ||
| Cash & equivalents | $1.51M | $547,890 |
| Short-term investments | $1.44M | $10.18M |
| Receivables | $15,500 | $188,400 |
| Current assets | $3.14M | $11.14M |
| PP&E, net | $358,767 | $362,936 |
| Intangibles | $534,198 | $623,945 |
| Total assets | $4.08M | $12.28M |
| Current liabilities | $3.72M | $3.75M |
| Total liabilities | $3.72M | $3.75M |
| Shareholders' equity | $356,744 | $8.53M |
| Shares outstanding | 8.88M | 6.92M |
| Cash flow statement | ||
| Operating cash flow | -$10.79M | -$8.23M |
| Capital expenditure | $116,069 | $106,189 |
| Free cash flow | -$10.91M | -$8.34M |
| Investing cash flow | $8.90M | $514,529 |
| Financing cash flow | $2.85M | $7.38M |
| Depreciation & amortization | $209,985 | $189,056 |
| Stock-based compensation | $3.33M | $2.81M |
| Share buybacks | $0 | — |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.